Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.56 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11732553 | 1.00 | PTPN1 (0.72) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL1749350 | 0.98 | PTPN1 (0.69) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11729220 | 0.95 | PTPN1 (0.64) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11731164 | 0.91 | KMT2A (0.66) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL125695 | 0.89 | PTPN1 (0.89) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL28656982 | 0.89 | PTPN1 (0.89) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL23005313 | 0.88 | LMNA (0.60) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL28241421 | 0.85 | PTPN1 (0.70) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11731779 | 0.85 | KMT2A (0.60) | PTPN1HPGDLMNAMAPTSMN1; SMN2 | |
| SCHEMBL19703413 | 0.84 | HPGD (1.00) | PTPN1HPGDMAPTNPSR1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589788-A | Toughness improvement method for thermal expansion microsphere foaming polypropylene material, and preparation method and application thereof | 华南理工大学 | 2023-08-15 | — | — | CN | claimed |
| CN-116589788-A | Toughness improvement method for thermal expansion microsphere foaming polypropylene material, and preparation method and application thereof | 华南理工大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-111363246-A | Polypropylene material capable of releasing negative ions as well as preparation method and application thereof | 浙江谱奈图新材料科技有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | disclosed |
| EP-0812212-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0758843-A4 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECH INC (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5709861-A | PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| EP-0812212-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5629020-A | Modified amino acids for drug delivery | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0758843-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | Emisphere Technologies, Inc. (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1996021464-A9 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996021464-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995028838-A1 | MODIFIED AMINO ACIDS FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| US-4001218-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | PTPN1 1550/4885HPGD 731/4885LMNA 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.